Front-line treatment of mantle cell lymphoma

Haematologica

Volumn 95, Issue 8, 2010, Pages 1241-1243

  Geisler, Christian H ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BENDAMUSTINE; BORTEZOMIB; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; EDITORIAL; ELDERLY CARE; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; COMBINED MODALITY THERAPY; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; HUMANS; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; NEUTROPENIA; PROGNOSIS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 77956029442     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.025627     Document Type: Editorial

References (24)

1. Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, et al; for the French GOELAMS group. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed Mantle Cell Lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010 Mar 10. [Epub ahead of print] PubMed PMID: 20220059.
2. Meusers P, Engelhard M, Bartels H, Binder T, Fülle HH, Görg K, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol. 1989;7(5):365-380.
3. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511-8.
4. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993;11(8):1573-1582.
5. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013-7023.
6. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984-9192.
7. Lefrere F, Delmer A, Levy V, Belanger C, Djabarri M, Arnulf B, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: A prospective study. Leukemia 2002;16(4):587-593.
8. van't Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J, et al. High-dose Ara-C and BEAM with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol. 2009;144(4):524-530.
9. Epner EM, Unger J, Miller T, Rimzsa L, Spier C, Leblanc M, Fisher R. A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma [abstract]. Blood. 2007;110:121a (abstract 387).
10. Geisler C, Kolstad A, Laurell A, Andersen N, Pedersen LB, et al. Longterm progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in-vivo purged stem cell rescue: a non-randomized phase-2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112(7):2687-2693.
11. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36):6101-6108.
12. Dreyling M, Lenz G, Hoster E, van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs event-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677-2684.
13. Andersen NS, Pedersen L, Elonen E, Johnson A, Kolstad A, Franssila K, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol. 2003;71(2):73-80.
14. Pott C, Hoster E, Delfau-Larue M-H, Beldjord K, Böttcher S, Asnafi V, et al. Molecular remission is an independent predictor of outcome in patients with mantle cell lymphoma after combined immunochemotherapy. A European MCL Intergroup Study, Blood. 2010;115(16):3215-3223.
15. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of event-free survival. J Clin Oncol. 2002;20(5):1288-1294.
16. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27(26):4365-4370.
17. Beers SA, French RR, Chan CH, Lim SH, Jarrett TC, Mora Vidal R, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: Implications for antibody selection. Blood. 2010 Mar 16. [Epub ahead of print]
18. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin- Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood.2008;111(2):558-565.
19. Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M, et al.; for the Nordic Lymphoma Group. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive firstline immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115(8):1530-1533.
20. Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al.; for the German Low-Grade Lymphoma Study Group.The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(10):3064-3071.
21. Rummel MJ, Niederle N, Maschmeyer G, Banat A, von Gruenhagen U, Losem C, et al. Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts), Nov 2009;114:405.
22. Kahl B, Li H, Smith MR, Gascoyne RD, Paietta E, Advani R, Horning S. The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 - A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. Blood 2009; 114(22): Abst. 1661.
23. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344-349.
24. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822-3829.